Claudio Liguori

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8543301/publications.pdf

Version: 2024-02-01

123 papers	3,030 citations	201575 27 h-index	214721 47 g-index
124 all docs	124 docs citations	124 times ranked	3841 citing authors

#	Article	IF	Citations
1	Orexinergic System Dysregulation, Sleep Impairment, and Cognitive Decline in Alzheimer Disease. JAMA Neurology, 2014, 71, 1498.	4.5	262
2	Subjective neurological symptoms frequently occur in patients with SARS-CoV2 infection. Brain, Behavior, and Immunity, 2020, 88, 11-16.	2.0	159
3	Biomarkers of conversion to Î±-synucleinopathy in isolated rapid-eye-movement sleep behaviour disorder. Lancet Neurology, The, 2021, 20, 671-684.	4.9	116
4	Obstructive Sleep Apnea is Associated With Early but Possibly Modifiable Alzheimerâ€™s Disease Biomarkers Changes. Sleep, 2017, 40, .	0.6	113
5	CSF lactate levels, Ï„ proteins, cognitive decline: a dynamic relationship in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 655-659.	0.9	108
6	Rapid eye movement sleep disruption and sleep fragmentation are associated with increased orexin-A cerebrospinal-fluid levels in mild cognitive impairment due to Alzheimer's disease. Neurobiology of Aging, 2016, 40, 120-126.	1.5	96
7	Sleep-disordered breathing and the risk of Alzheimer's disease. Sleep Medicine Reviews, 2021, 55, 101375.	3.8	79
8	Alzheimer's disease and late-onset epilepsy of unknown origin: two faces of beta amyloid pathology. Neurobiology of Aging, 2019, 73, 61-67.	1.5	75
9	Cerebrospinal fluid lactate levels and brain [18F]FDG PET hypometabolism within the default mode network in Alzheimerâ€™s disease. European Journal of Nuclear Medicine and Molecular Imaging, 2016, 43, 2040-2049.	3.3	73
10	Epilepsy, amyloid-Î², and D1 dopamine receptors: a possible pathogenetic link?. Neurobiology of Aging, 2016, 48, 161-171.	1.5	71
11	Self-reported needs of patients with Parkinsonâ€™s disease during COVID-19 emergency in Italy. Neurological Sciences, 2020, 41, 1373-1375.	0.9	59
12	Rotigotine may improve sleep architecture in Parkinson's disease: a double-blind, randomized, placebo-controlled polysomnographic study. Sleep Medicine, 2016, 21, 140-144.	0.8	55
13	Obstructive sleep apnea may induce orexinergic system and cerebral Î²-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?. Sleep Medicine, 2019, 56, 171-176.	0.8	53
14	Physical Activity Changes and Correlate Effects in Patients with Parkinson's Disease during <scp>COVID</scp>â€19 Lockdown. Movement Disorders Clinical Practice, 2020, 7, 797-802.	0.8	53
15	COVID-19: dealing with a potential risk factor for chronic neurological disorders. Journal of Neurology, 2021, 268, 1171-1178.	1.8	50
16	Continuous Positive Airway Pressure Treatment Increases Serum Vitamin D Levels in Male Patients with Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2015, 11, 603-607.	1.4	47
17	Sleep-Wake Cycle in Alzheimerâ€™s Disease Is Associated with Tau Pathology and Orexin Dysregulation. Journal of Alzheimer's Disease, 2020, 74, 501-508.	1.2	47
18	Orexin and Alzheimerâ€™s Disease. Current Topics in Behavioral Neurosciences, 2016, 33, 305-322.	0.8	45

#	Article	IF	Citations
19	Effects of anti-seizure medications on sleep architecture and daytime sleepiness in patients with epilepsy: A literature review. Sleep Medicine Reviews, 2021, 60, 101559.	3.8	44
20	Integrating postural and vestibular dimensions to depict impairment in moderateâ€toâ€severe obstructive sleep apnea syndrome patients. Journal of Sleep Research, 2017, 26, 487-494.	1.7	43
21	Efficacy and tolerability of perampanel and levetiracetam as first add-on therapy in patients with epilepsy: A retrospective single center study. Epilepsy and Behavior, 2018, 80, 173-176.	0.9	40
22	Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimerâ€™s disease. Journal of Neurology, 2017, 264, 2215-2223.	1.8	39
23	Sleep dysregulation, memory impairment, and CSF biomarkers during different levels of neurocognitive functioning in Alzheimerâ€™s disease course. Alzheimer's Research and Therapy, 2020, 12, 5.	3.0	39
24	<scp>CSF</scp> betaâ€amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?. Journal of Sleep Research, 2014, 23, 420-424.	1.7	37
25	Sleep disorders in myotonic dystrophy type 2: a controlled polysomnographic study and selfâ€reported questionnaires. European Journal of Neurology, 2014, 21, 929-934.	1.7	37
26	PERMIT study: a global pooled analysis study of the effectiveness and tolerability of perampanel in routine clinical practice. Journal of Neurology, 2022, 269, 1957-1977.	1.8	34
27	Homovanillic acid in CSF of mild stage Parkinson's disease patients correlates with motor impairment. Neurochemistry International, 2017, 105, 58-63.	1.9	33
28	Nocturnal frontal lobe epilepsy with paroxysmal arousals due to CHRNA2 loss of function. Neurology, 2015, 84, 1520-1528.	1.5	32
29	Metabolic dysfunction in OSA: Is there something new under the sun?. Journal of Sleep Research, 2022, 31, e13418.	1.7	31
30	Subthalamic nucleus deep brain stimulation on motor-symptoms of Parkinsonâ€™s disease: Focus on neurochemistry. Progress in Neurobiology, 2017, 151, 157-174.	2.8	30
31	Vitamin D status of male OSAS patients improved after long-term CPAP treatment mainly in obese subjects. Sleep Medicine, 2017, 29, 81-85.	0.8	30
32	In vivo human molecular neuroimaging of dopaminergic vulnerability along the Alzheimerâ€™s disease phases. Alzheimer's Research and Therapy, 2021, 13, 187.	3.0	29
33	Daytime sleepiness may be an independent symptom unrelated to sleep quality in Parkinsonâ€™s disease. Journal of Neurology, 2019, 266, 636-641.	1.8	28
34	Neuropsychiatric symptoms differently affect mild cognitive impairment and Alzheimerâ€™s disease patients: a retrospective observational study. Neurological Sciences, 2019, 40, 1377-1382.	0.9	27
35	Optic Nerve Dysfunction in Obstructive Sleep Apnea: An Electrophysiological Study. Sleep, 2016, 39, 19-23.	0.6	26
36	Obstructive sleep apnoea as a risk factor for osteopenia and osteoporosis in the male population. European Respiratory Journal, 2016, 47, 987-990.	3.1	26

#	Article	IF	Citations
37	Cerebrospinal-fluid orexin levels and daytime somnolence in frontotemporal dementia. Journal of Neurology, 2014, 261, 1832-1836.	1.8	25
38	Safinamide effect on sleep disturbances and daytime sleepiness in motor fluctuating Parkinson's disease patients: A validated questionnaires-controlled study. Parkinsonism and Related Disorders, 2018, 57, 80-81.	1.1	25
39	When Cognitive Decline and Depression Coexist in the Elderly: CSF Biomarkers Analysis Can Differentiate Alzheimer's Disease from Late-Life Depression. Frontiers in Aging Neuroscience, 2018, 10, 38.	1.7	25
40	Sleep-Wake Cycle and Daytime Sleepiness in the Myotonic Dystrophies. Journal of Neurodegenerative Diseases, 2013, 2013, 1-13.	1.1	23
41	Sleep apnoeas may represent a reversible risk factor for amyloid-Î² pathology. Brain, 2017, 140, e75-e75.	3.7	23
42	Cerebrospinal Fluid Orexin Levels and Nocturnal Sleep Disruption in Alzheimerâ€™s Disease Patients Showing Neuropsychiatric Symptoms. Journal of Alzheimer's Disease, 2018, 66, 993-999.	1.2	22
43	Cerebral glucose metabolism in idiopathic REM sleep behavior disorder is different from tau-related and Î±-synuclein-related neurodegenerative disorders: A brain [18F]FDG PET study. Parkinsonism and Related Disorders, 2019, 64, 97-105.	1.1	22
44	Sleep disorders in spinal and bulbar muscular atrophy (Kennedyâ€™s disease): a controlled polysomnographic and self-reported questionnaires study. Journal of Neurology, 2014, 261, 889-893.	1.8	21
45	Cognitive performances in patients affected by late-onset epilepsy with unknown etiology: A 12-month follow-up study. Epilepsy and Behavior, 2019, 101, 106592.	0.9	21
46	Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: a retrospective questionnaire analysis. British Journal of Clinical Pharmacology, 2019, 85, 240-244.	1.1	21
47	Mechanisms of action underlying the efficacy of deep brain stimulation of the subthalamic nucleus in Parkinson's disease: central role of disease severity. European Journal of Neuroscience, 2019, 49, 805-816.	1.2	20
48	Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time. Sleep and Breathing, 2016, 20, 277-283.	0.9	19
49	Comparative Sleep Disturbances in Myotonic Dystrophy Types 1 and 2. Current Neurology and Neuroscience Reports, 2018, 18, 102.	2.0	19
50	Daytime autonomic activity in idiopathic rapid eye movement sleep behavior disorder: a preliminary study. Sleep Medicine, 2018, 52, 163-167.	0.8	19
51	Shedding Light on Nocturnal Movements in Parkinsonâ€™s Disease: Evidence from Wearable Technologies. Sensors, 2020, 20, 5171.	2.1	18
52	Sleep problems affect quality of life in Parkinson's disease along disease progression. Sleep Medicine, 2021, 81, 307-311.	0.8	18
53	Perampanel effectiveness and tolerability in patients with epilepsy at long-term follow-up. Epilepsy and Behavior, 2021, 121, 108069.	0.9	18
54	Complement system dysregulation in patients affected by Idiopathic Generalized Epilepsy and the effect of antiepileptic treatment. Epilepsy Research, 2017, 137, 107-111.	0.8	17

#	Article	IF	Citations
55	Effective treatment of restless legs syndrome by safinamide in Parkinson's disease patients. Sleep Medicine, 2018, 41, 113-114.	0.8	16
56	Lacosamide may improve cognition in patients with focal epilepsy: EpiTrack to compare cognitive side effects of lacosamide and carbamazepine. Epilepsy & Behavior Case Reports, 2018, 10, 35-37.	1.5	16
57	Dysregulation of the orexin/hypocretin system is not limited to narcolepsy but has farâ€reaching implications for neurological disorders. European Journal of Neuroscience, 2021, 53, 1136-1154.	1.2	16
58	Comparison of the effectiveness and tolerability of perampanel and brivaracetam: a realâ€world, observational, retrospective study. Epileptic Disorders, 2020, 22, 309-316.	0.7	15
59	The Importance of Diagnosing and the Clinical Potential of Treating Obstructive Sleep Apnea to Delay Mild Cognitive Impairment and Alzheimerâ€™s Disease: A Special Focus on Cognitive Performance. Journal of Alzheimer's Disease Reports, 2021, 5, 515-533.	1.2	15
60	Long-term efficacy and safety of lacosamide and levetiracetam monotherapy in elderly patients with focal epilepsy: A retrospective study. Epilepsy and Behavior, 2019, 94, 178-182.	0.9	14
61	Obstructive sleep apnea syndrome and Alzheimerâ€™s disease pathology: may continuous positive airway pressure treatment delay cognitive deterioration?. Sleep and Breathing, 2021, 25, 2135-2139.	0.9	14
62	Frequency of Non-motor Symptoms in Parkinson's Patients With Motor Fluctuations. Frontiers in Neurology, 2021, 12, 678373.	1.1	14
63	Effects of adjunctive perampanel on sleep quality, daytime somnolence and cognition in refractory focal epilepsy: further data.. Epilepsy and Behavior, 2017, 67, 137-138.	0.9	13
64	Postural and vestibular changes related to CPAP treatment in moderate-to-severe OSA patients: a 12-month longitudinal study. Sleep and Breathing, 2019, 23, 665-672.	0.9	13
65	CSF Biomarkers for Early Diagnosis of Synucleinopathies: Focus on Idiopathic RBD. Current Neurology and Neuroscience Reports, 2019, 19, 3.	2.0	13
66	18F-FDG PET, cognitiveÂfunctioning, and CSF biomarkers in patients with obstructive sleep apnoea before and after continuous positive airway pressure treatment. Journal of Neurology, 2022, 269, 5356-5367.	1.8	13
67	Estrogen Deficiency Hampers the Beneficial Effect of Continuous Positive Airway Pressure Therapy on Serum Vitamin D Concentrations in Postmenopausal Women Affected by Obstructive Sleep Apnea. Journal of Clinical Sleep Medicine, 2015, 11, 1473-1474.	1.4	12
68	Cerebrospinal-fluid Alzheimerâ€™s Disease Biomarkers and Blood-Brain Barrier Integrity in a Natural Population of Cognitive Intact Parkinsonâ€™s Disease Patients. CNS and Neurological Disorders - Drug Targets, 2017, 16, 339-345.	0.8	12
69	Continuous Positive Airway Pressure Treatment May Improve Optic Nerve Function in Obstructive Sleep Apnea: An Electrophysiological Study. Journal of Clinical Sleep Medicine, 2018, 14, 953-958.	1.4	12
70	Perampanel Increases Cortical EEG Fast Activity in Child and Adult Patients Affected by Epilepsy: A Quantitative EEG Study. Clinical EEG and Neuroscience, 2021, 52, 360-370.	0.9	11
71	Depressive and anxiety symptoms in patients with SARS-CoV2 infection. Journal of Affective Disorders, 2021, 278, 339-340.	2.0	11
72	Sleep disorders and late-onset epilepsy of unknown origin: Understanding new trajectories to brain amyloidopathy. Mechanisms of Ageing and Development, 2021, 194, 111434.	2.2	11

#	Article	IF	Citations
73	Chronic dopaminergic treatment in restless legs syndrome: does it affect the autonomic nervous system?. Sleep Medicine, 2015, 16, 1071-1076.	0.8	10
74	Effective treatment of nocturnal frontal lobe epilepsy with lacosamide: a report of two cases. Sleep Medicine, 2016, 23, 121-122.	0.8	10
75	Symptomatic nonconvulsive status epilepticus erroneously suggestive of sporadic Creutzfeldtâ€“Jakob disease. Journal of the Neurological Sciences, 2015, 348, 274-276.	0.3	9
76	Does continuous positive airway pressure treatment affect autonomic nervous system in patients with severe obstructive sleep apnea?. Sleep Medicine, 2018, 42, 68-72.	0.8	9
77	Is It Time to Consider Obstructive Sleep Apnea Syndrome a Risk Factor for Alzheimerâ€™s Disease?. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 855-856.	2.5	9
78	Preliminary evidence about irritability in patients with epilepsy treated by perampanel as first addâ€on therapy compared to levetiracetam and valproic acid. CNS Neuroscience and Therapeutics, 2019, 25, 632-637.	1.9	9
79	Autonomic symptoms, cardiovascular and sudomotor evaluation in de novo type 1 narcolepsy. Clinical Autonomic Research, 2020, 30, 557-562.	1.4	9
80	Cognitive functioning, cerebrospinal fluid Alzheimer's disease biomarkers and cerebral glucose metabolism in lateâ€onset epilepsy of unknown aetiology: A prospective study. European Journal of Neuroscience, 2022, 56, 5384-5396.	1.2	9
81	Nocturnal Hypoxia and Sleep Fragmentation May Drive Neurodegenerative Processes: The Compared Effects of Obstructive Sleep Apnea Syndrome and Periodic Limb Movement Disorder on Alzheimerâ€™s Disease Biomarkers. Journal of Alzheimer's Disease, 2022, 88, 127-139.	1.2	8
82	May CSF beta-amyloid and tau proteins levels be influenced by long treatment duration and stable medication in narcolepsy?. Sleep Medicine, 2014, 15, 1424.	0.8	7
83	Does fatigue in Parkinsonâ€™s disease correlate with autonomic nervous system dysfunction?. Neurological Sciences, 2018, 39, 2169-2174.	0.9	7
84	Sleepâ^'wake cycle dysregulation in idiopathic REM sleep behaviour disorder. Journal of Sleep Research, 2021, 30, e13234.	1.7	7
85	Levetiracetam, lamotrigine and carbamazepine: which monotherapy during pregnancy?. Neurological Sciences, 2022, 43, 1993-2001.	0.9	7
86	Depressive symptoms in patients with epilepsy and clinically associated features in a single tertiary center. Neurological Sciences, 2022, 43, 1965-1974.	0.9	7
87	More than sleep and wake disturbances: an actigraphic study showing the sleep-wake pattern dysregulation in epilepsy.. Seizure: the Journal of the British Epilepsy Association, 2021, 94, 95-99.	0.9	7
88	Development of Collateral Veins as a Favorable Prognostic Factor for Complete Recovery in Cerebral Venous Thrombosis Due to Tribulus Terrestris. International Journal of Stroke, 2015, 10, E66-E67.	2.9	6
89	Lateralization of cochlear dysfunction as a specific biomarker of Parkinsonâ€™s disease. Brain Communications, 2020, 2, fcaa144.	1.5	6
90	Dyspnea perception and neurological symptoms in non-severe COVID-19 patients. Neurological Sciences, 2020, 41, 2671-2674.	0.9	6

#	Article	IF	Citations
91	Obstructive Sleep Apnea, Palatal Morphology, and Aortic Dilatation in Marfan Syndrome Growing Subjects: A Retrospective Study. International Journal of Environmental Research and Public Health, 2021, 18, 3045.	1.2	6
92	Effects of melatonin prolonged-release on both sleep and motor symptoms in Parkinsonâ€™s disease: a preliminary evidence. Neurological Sciences, 2022, 43, 5355-5362.	0.9	6
93	Not just a Snapshot: An Italian Longitudinal Evaluation of Stability of Gut Microbiota Findings in Parkinsonâ€™s Disease. Brain Sciences, 2022, 12, 739.	1.1	6
94	Autonomic functions in focal epilepsy: A comparison between lacosamide and carbamazepine monotherapy. Journal of the Neurological Sciences, 2020, 418, 117095.	0.3	5
95	Assessment of self-reported and objective daytime sleepiness in adult-onset myotonic dystrophy type 1. Journal of Clinical Sleep Medicine, 2021, 17, 2383-2391.	1.4	5
96	The actigraphic documentation of circadian sleep-wake rhythm dysregulation in myotonic dystrophy type 1. Sleep Medicine, 2021, 88, 134-139.	0.8	5
97	Perampanel may represent an effective treatment for the prevention of migraine comorbid with epilepsy. Epilepsy and Behavior, 2021, 125, 108391.	0.9	5
98	May a suspicious psychiatric disorder hide sporadic hemiplegic migraine? Genetic test as prompting factor for diagnosis. Neurological Sciences, 2013, 34, 1845-1846.	0.9	4
99	Rotigotine effect on sleep in a de novo Parkinson's Disease patient affected by periodic limb movement disorder. Parkinsonism and Related Disorders, 2015, 21, 1476-1478.	1.1	4
100	Bilateral thalamic stroke due to nasal ephedrine and naphazoline use. Neurological Sciences, 2015, 36, 1285-1286.	0.9	4
101	New revolution in the assessment of cerebrospinal fluid orexinâ€A: Enzymeâ€linked immunosorbent assay!. Psychiatry and Clinical Neurosciences, 2019, 73, 194-195.	1.0	4
102	Seasonality of restless legs syndrome: symptom variability in winter and summer times. Sleep Medicine, 2020, 66, 10-14.	0.8	4
103	Laterality of Auditory Dysfunction in Parkinson's Disease. Movement Disorders, 2020, 35, 1283-1284.	2.2	4
104	PAP use in mild cognitive impairment to delay progression to dementia. Journal of Clinical Sleep Medicine, 2020, 16, 1397-1397.	1.4	4
105	Pitolisant for treating narcolepsy comorbid with Parkinson's disease. Sleep Medicine, 2020, 69, 86-87.	0.8	4
106	CSF Levels of the Endocannabinoid Anandamide are Reduced in Patients with Untreated Narcolepsy Type 1: A Pilot Study. CNS and Neurological Disorders - Drug Targets, 2020, 19, 142-147.	0.8	4
107	Effects of epilepsy treatment on sleep architecture and daytime sleepiness: An evidenceâ€based review of objective sleep metrics. Epilepsia, 2014, 55, 777-778.	2.6	3
108	MicroRNA expression is dysregulated in narcolepsy: a new evidence?. Sleep Medicine, 2015, 16, 1027-1028.	0.8	3

#	Article	IF	Citations
109	Biomarkers of Cerebral Glucose Metabolism and Neurodegeneration in Parkinsonâ€™s Disease: A Cerebrospinal Fluid-Based Study. Journal of Parkinson's Disease, 2022, 12, 537-544.	1.5	3
110	Unexpected total recovery in a patient with post-anoxic complete alpha coma predicted by recording of cortical SEPs. Clinical Neurophysiology, 2013, 124, 2450-2453.	0.7	2
111	Lacosamide as add-on treatment of focal symptomatic epilepsy in a patient with alcoholic liver cirrhosis. Epilepsy & Behavior Case Reports, 2014, 2, 161-163.	1.5	2
112	Fronto-central monomorphic theta activity as EEG pattern of ictal psychosis. Journal of the Neurological Sciences, 2014, 337, 240-242.	0.3	2
113	Multiple sleep latency test may be not sensitive in obstructive sleep apnea with comorbid narcolepsy revealed by low cerebrospinal fluid orexin levels. Sleep Medicine, 2014, 15, 1171.	0.8	2
114	Commentary: Clinical Correlates of Raphe Serotonergic Dysfunction in Early Parkinsonâ€™s Disease. Frontiers in Neurology, 2015, 6, 261.	1.1	2
115	Refractory restless legs syndrome remitting after dual kidney transplantation. Parkinsonism and Related Disorders, 2015, 21, 81-83.	1.1	2
116	Obstructive sleep apnoea and bone health. European Respiratory Journal, 2016, 48, 1249-1250.	3.1	2
117	Commentary: Sleep Changes without Medial Temporal Lobe or Brain Cortical Changes in Community-Dwelling Individuals with Subjective Cognitive Decline. Frontiers in Neurology, 2017, 8, 262.	1.1	2
118	Perampanel effects on cognition and quantitative EEG in patients with epilepsy. Epilepsy and Behavior, 2021, 117, 107803.	0.9	2
119	Obstructive sleep apnoea as a risk factor for osteopenia and osteoporosis in the male population: further data and comments. European Respiratory Journal, 2017, 49, 1602471.	3.1	1
120	Intermittent Short Sleep May Contribute to Orexinergic Signaling Dysregulation in Alzheimerâ€™s Disease. Sleep, 2017, 40, .	0.6	1
121	Physical activity contradictorily affects bone mineral density in obstructive sleep apnea patients at different ages. Sleep Medicine, 2017, 32, 273.	0.8	0
122	Compliance with levodopa-carbidopa intestinal gel in a selected population in central south Italy: Beyond sex, a possible gender effect. Parkinsonism and Related Disorders, 2020, 73, 57-59.	1.1	0
123	Sleep and wake impairment in patients with SARS-CoV2 infection. Sleep Medicine, 2020, 73, 177-178.	0.8	0